Letrozole
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
PfizerSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Arimidex Pfizer | Phase 1/2 | CCC |
FULVESTRANT Pfizer | Phase 1/2 | CCC |
EXEMESTANE Pfizer | Phase 1/2 | CCC |
pf-06873600 Pfizer | Phase 1/2 | CCC |
Same molecule, other indications
Letrozole is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →